PL2433940T3 - Pochodna spiroimidazolonu - Google Patents

Pochodna spiroimidazolonu

Info

Publication number
PL2433940T3
PL2433940T3 PL10769728T PL10769728T PL2433940T3 PL 2433940 T3 PL2433940 T3 PL 2433940T3 PL 10769728 T PL10769728 T PL 10769728T PL 10769728 T PL10769728 T PL 10769728T PL 2433940 T3 PL2433940 T3 PL 2433940T3
Authority
PL
Poland
Prior art keywords
spiroimidazolone
derivative
spiroimidazolone derivative
Prior art date
Application number
PL10769728T
Other languages
English (en)
Inventor
Toru Esaki
Yoshikazu Nishimura
Yoshiaki Isshiki
Naoki Okamoto
Yoshiyuki Furuta
Akemi Mizutani
Masateru Ohta
Wayne Wen Lai
Tomoya Kotake
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PL2433940T3 publication Critical patent/PL2433940T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL10769728T 2009-04-28 2010-04-27 Pochodna spiroimidazolonu PL2433940T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009109256 2009-04-28
PCT/JP2010/057432 WO2010126030A1 (ja) 2009-04-28 2010-04-27 スピロイミダゾロン誘導体
EP10769728.6A EP2433940B9 (en) 2009-04-28 2010-04-27 Spiroimidazolone derivative

Publications (1)

Publication Number Publication Date
PL2433940T3 true PL2433940T3 (pl) 2015-03-31

Family

ID=43032174

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10769728T PL2433940T3 (pl) 2009-04-28 2010-04-27 Pochodna spiroimidazolonu

Country Status (12)

Country Link
US (2) US9169254B2 (pl)
EP (1) EP2433940B9 (pl)
JP (1) JP5671453B2 (pl)
CY (1) CY1115744T1 (pl)
DK (1) DK2433940T3 (pl)
ES (1) ES2525353T3 (pl)
HR (1) HRP20141126T1 (pl)
PL (1) PL2433940T3 (pl)
PT (1) PT2433940E (pl)
SI (1) SI2433940T1 (pl)
TW (1) TWI496782B (pl)
WO (1) WO2010126030A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525353T3 (es) * 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
US9133182B2 (en) * 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
CA2892621C (en) * 2012-12-10 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative
EP3153166B1 (en) * 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
TWI686392B (zh) * 2014-06-09 2020-03-01 日商中外製藥股份有限公司 含有乙內醯脲衍生物之醫藥組合物
JP6290138B2 (ja) * 2014-06-09 2018-03-07 中外製薬株式会社 ヒダントイン誘導体含有医薬組成物
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
CN105017252B (zh) * 2015-06-30 2017-04-12 河南师范大学 具有生物活性的1,3,8‑三氮杂螺[4,5]癸烷‑2‑胍‑4‑酮类化合物及其制备方法和应用
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
TWI753037B (zh) 2016-10-26 2022-01-21 美商星座製藥公司 Lsd1抑制劑及其用途
RU2747400C2 (ru) * 2016-11-14 2021-05-04 Байондис Б.В. СПОСОБ ПОЛУЧЕНИЯ МОНОЗАЩИЩЕННЫХ α,ω-ДИАМИНОАЛКАНОВ
IT201600130729A1 (it) * 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione degli intermedi del delmopinolo
CN108003037B (zh) * 2018-01-18 2020-07-24 上海仁实医药科技有限公司 一种n-甲基-5-己烯-1-胺的合成工艺
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US20210290541A1 (en) 2018-07-30 2021-09-23 Chugai Seiyaku Kabushiki Kaisha Solid dispersion of hydantoin derivative
US20240018144A1 (en) * 2020-10-12 2024-01-18 The Regents Of The University Of Michigan Synthesis of EGFR Modulators
CN112142634A (zh) * 2020-11-02 2020-12-29 广州市科虎生物技术研究开发中心 一种（2-羧乙基）二甲基氯化锍的制备方法
CN112574226A (zh) * 2020-12-15 2021-03-30 海门华祥医药科技有限公司 5,6-亚甲基二氧基吲哚的制备方法
CN114409569A (zh) * 2021-12-23 2022-04-29 江苏长青农化股份有限公司 一种手性稻瘟酰胺的制备方法
JPWO2024143501A1 (pl) 2022-12-28 2024-07-04
CN116969831B (zh) * 2023-08-01 2025-09-23 菏泽皓元医药科技有限公司 一种莫奈太尔的中间体及其制备方法
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
WO2025226895A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Agonists of parathyroid hormone 1 and incretin receptors comprising substituted or modified diaminomethylene pyrimidine-2,4,6-triones
WO2025226892A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Spirocycle-containing diaminomethylene pyrimidine-2,4,6-trione agonists of parathyroid hormone 1 and incretin receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
AU765729B2 (en) 1998-12-11 2003-09-25 F. Hoffmann-La Roche Ag Cyclic hydrazine derivatives as TNF-alpha inhibitors
EP1321141A4 (en) 2000-08-30 2004-02-18 Teijin Ltd INHIBITORS OF PARATHORMONE PRODUCTION CONTAINING VITAMIN D3 DERIVATIVES
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070123548A1 (en) 2004-02-11 2007-05-31 Cowan David J Pth agonists
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2007135417A1 (en) * 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
CN101472924A (zh) * 2006-06-20 2009-07-01 惠氏公司 Kv1.5钾通道抑制剂
CA2689560A1 (en) * 2007-06-07 2008-12-11 F.Hoffmann-La Roche Ag Prolinamide derivatives as nk3 antagonists
CL2008003651A1 (es) * 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
ES2525353T3 (es) 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
CA2892621C (en) 2012-12-10 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative

Also Published As

Publication number Publication date
TW201103938A (en) 2011-02-01
WO2010126030A1 (ja) 2010-11-04
TWI496782B (zh) 2015-08-21
DK2433940T3 (en) 2015-01-12
EP2433940A4 (en) 2012-10-10
JP5671453B2 (ja) 2015-02-18
US20160016956A1 (en) 2016-01-21
PT2433940E (pt) 2014-12-12
US9169254B2 (en) 2015-10-27
HRP20141126T1 (hr) 2015-01-30
EP2433940B9 (en) 2015-10-28
EP2433940B1 (en) 2014-09-24
US20120270838A1 (en) 2012-10-25
US9487517B2 (en) 2016-11-08
CY1115744T1 (el) 2017-01-25
ES2525353T3 (es) 2014-12-22
JPWO2010126030A1 (ja) 2012-11-01
EP2433940A1 (en) 2012-03-28
SI2433940T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
IL220616A0 (en) Novel 3 - hydroxy - 5 - arylisothiazole derivative
PL2433940T3 (pl) Pochodna spiroimidazolonu
ZA201203205B (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
EP2495238A4 (en) NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
PL2397480T3 (pl) Pochodna diazepinodionu
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
ZA201104991B (en) Deoxyactagardine derivatives
ZA201202899B (en) 5-hydroxypyrimidine-4-carboxamide derivative
IL216761A0 (en) Pyrazinooxazepine derivatives
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives